A májfunkció romlásának rizikófaktorai sikeres vesetranszplantációt követően

Borda Bernadett, Nemes Attila, Lengyel Csaba, T. Várkonyi, Rárosi Ferenc, Keresztes Csilla, Ottlakán Aurél, G. Lazar

Research output: Article

Abstract

Introduction: Increase of liver function is one of the most common complications after kidney transplantation due to the use of immunosuppressive therapy and hyperlipidemia in addition to hepatitis C virus (HCV) infection. Method: Following the selection criteria (n = 59), the study is based on applied immunosuppressive therapy, baseline data of patients, further correlation between HCV and liver function deterioration. Patients were subjected to fasting laboratory examination to monitor serum electrolytes, uric acid and albumin levels. We looked at the effects of immunosuppressive therapy on the lipids (TG, TC, HDL, LDL) and liver enzymes (GOT, GPT, ALP, GGT). The analysis of the relationship between lipids and liver enzymes was also included in our study. Results: The data basics were not significantly different between the tacrolimus and the cyclosporine groups. In the laboratory results, Mg levels were significantly different between the two groups (p = 0.044). The impact of HCV on the liver function was significantly different on GGT (p = 0.008). We examed the lipids and liver function level between the tacrolimus and the patients receiving cyclosporine-based immunosuppression and the total cholesterol (p = 0.005) and GOT (p = 0.05) were significantly different between the two groups. Hyperlipidemia was associated with 26% of patients taking tacrolimus-based immunosuppression, and 89% of those receiving cyclosporine; the difference was significant (p = 0.002). Regarding the effect of hyperlipidemia on liver enzymes, ALP (p = 0.006) and GGT (p = 0.0001) were significantly higher. Conclusion: Increases in hepatic enzymes, ALT and GGT indicate the damage to hepatocytes. Beside the increase of liver function, which is the main risk factor in hepatitis on HCV soil, the applied immunosuppressive therapy and hyperlipidemia lead to degradation of allograft function and long-term graft loss.

Original languageHungarian
Pages (from-to)186-190
Number of pages5
JournalOrvosi Hetilap
Volume160
Issue number5
DOIs
Publication statusPublished - febr. 1 2019

Fingerprint

Kidney Transplantation
Liver
Immunosuppressive Agents
Hyperlipidemias
Hepacivirus
Tacrolimus
Cyclosporine
Lipids
Immunosuppression
Virus Diseases
Enzymes
Therapeutics
Uric Acid
Patient Selection
Electrolytes
Hepatitis
Allografts
Hepatocytes
Albumins
Fasting

Keywords

  • Cyclosporine
  • Hyperlipidemia
  • Liver function
  • Tacrolimus

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A májfunkció romlásának rizikófaktorai sikeres vesetranszplantációt követően. / Bernadett, Borda; Attila, Nemes; Csaba, Lengyel; Várkonyi, T.; Ferenc, Rárosi; Csilla, Keresztes; Aurél, Ottlakán; Lazar, G.

In: Orvosi Hetilap, Vol. 160, No. 5, 01.02.2019, p. 186-190.

Research output: Article

Bernadett, B, Attila, N, Csaba, L, Várkonyi, T, Ferenc, R, Csilla, K, Aurél, O & Lazar, G 2019, 'A májfunkció romlásának rizikófaktorai sikeres vesetranszplantációt követően', Orvosi Hetilap, vol. 160, no. 5, pp. 186-190. https://doi.org/10.1556/650.2019.31257
Bernadett, Borda ; Attila, Nemes ; Csaba, Lengyel ; Várkonyi, T. ; Ferenc, Rárosi ; Csilla, Keresztes ; Aurél, Ottlakán ; Lazar, G. / A májfunkció romlásának rizikófaktorai sikeres vesetranszplantációt követően. In: Orvosi Hetilap. 2019 ; Vol. 160, No. 5. pp. 186-190.
@article{fc454574b4344cc8af496a311c740b08,
title = "A m{\'a}jfunkci{\'o} roml{\'a}s{\'a}nak rizik{\'o}faktorai sikeres vesetranszplant{\'a}ci{\'o}t k{\"o}vetően",
abstract = "Introduction: Increase of liver function is one of the most common complications after kidney transplantation due to the use of immunosuppressive therapy and hyperlipidemia in addition to hepatitis C virus (HCV) infection. Method: Following the selection criteria (n = 59), the study is based on applied immunosuppressive therapy, baseline data of patients, further correlation between HCV and liver function deterioration. Patients were subjected to fasting laboratory examination to monitor serum electrolytes, uric acid and albumin levels. We looked at the effects of immunosuppressive therapy on the lipids (TG, TC, HDL, LDL) and liver enzymes (GOT, GPT, ALP, GGT). The analysis of the relationship between lipids and liver enzymes was also included in our study. Results: The data basics were not significantly different between the tacrolimus and the cyclosporine groups. In the laboratory results, Mg levels were significantly different between the two groups (p = 0.044). The impact of HCV on the liver function was significantly different on GGT (p = 0.008). We examed the lipids and liver function level between the tacrolimus and the patients receiving cyclosporine-based immunosuppression and the total cholesterol (p = 0.005) and GOT (p = 0.05) were significantly different between the two groups. Hyperlipidemia was associated with 26{\%} of patients taking tacrolimus-based immunosuppression, and 89{\%} of those receiving cyclosporine; the difference was significant (p = 0.002). Regarding the effect of hyperlipidemia on liver enzymes, ALP (p = 0.006) and GGT (p = 0.0001) were significantly higher. Conclusion: Increases in hepatic enzymes, ALT and GGT indicate the damage to hepatocytes. Beside the increase of liver function, which is the main risk factor in hepatitis on HCV soil, the applied immunosuppressive therapy and hyperlipidemia lead to degradation of allograft function and long-term graft loss.",
keywords = "Cyclosporine, Hyperlipidemia, Liver function, Tacrolimus",
author = "Borda Bernadett and Nemes Attila and Lengyel Csaba and T. V{\'a}rkonyi and R{\'a}rosi Ferenc and Keresztes Csilla and Ottlak{\'a}n Aur{\'e}l and G. Lazar",
year = "2019",
month = "2",
day = "1",
doi = "10.1556/650.2019.31257",
language = "Hungarian",
volume = "160",
pages = "186--190",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "5",

}

TY - JOUR

T1 - A májfunkció romlásának rizikófaktorai sikeres vesetranszplantációt követően

AU - Bernadett, Borda

AU - Attila, Nemes

AU - Csaba, Lengyel

AU - Várkonyi, T.

AU - Ferenc, Rárosi

AU - Csilla, Keresztes

AU - Aurél, Ottlakán

AU - Lazar, G.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Introduction: Increase of liver function is one of the most common complications after kidney transplantation due to the use of immunosuppressive therapy and hyperlipidemia in addition to hepatitis C virus (HCV) infection. Method: Following the selection criteria (n = 59), the study is based on applied immunosuppressive therapy, baseline data of patients, further correlation between HCV and liver function deterioration. Patients were subjected to fasting laboratory examination to monitor serum electrolytes, uric acid and albumin levels. We looked at the effects of immunosuppressive therapy on the lipids (TG, TC, HDL, LDL) and liver enzymes (GOT, GPT, ALP, GGT). The analysis of the relationship between lipids and liver enzymes was also included in our study. Results: The data basics were not significantly different between the tacrolimus and the cyclosporine groups. In the laboratory results, Mg levels were significantly different between the two groups (p = 0.044). The impact of HCV on the liver function was significantly different on GGT (p = 0.008). We examed the lipids and liver function level between the tacrolimus and the patients receiving cyclosporine-based immunosuppression and the total cholesterol (p = 0.005) and GOT (p = 0.05) were significantly different between the two groups. Hyperlipidemia was associated with 26% of patients taking tacrolimus-based immunosuppression, and 89% of those receiving cyclosporine; the difference was significant (p = 0.002). Regarding the effect of hyperlipidemia on liver enzymes, ALP (p = 0.006) and GGT (p = 0.0001) were significantly higher. Conclusion: Increases in hepatic enzymes, ALT and GGT indicate the damage to hepatocytes. Beside the increase of liver function, which is the main risk factor in hepatitis on HCV soil, the applied immunosuppressive therapy and hyperlipidemia lead to degradation of allograft function and long-term graft loss.

AB - Introduction: Increase of liver function is one of the most common complications after kidney transplantation due to the use of immunosuppressive therapy and hyperlipidemia in addition to hepatitis C virus (HCV) infection. Method: Following the selection criteria (n = 59), the study is based on applied immunosuppressive therapy, baseline data of patients, further correlation between HCV and liver function deterioration. Patients were subjected to fasting laboratory examination to monitor serum electrolytes, uric acid and albumin levels. We looked at the effects of immunosuppressive therapy on the lipids (TG, TC, HDL, LDL) and liver enzymes (GOT, GPT, ALP, GGT). The analysis of the relationship between lipids and liver enzymes was also included in our study. Results: The data basics were not significantly different between the tacrolimus and the cyclosporine groups. In the laboratory results, Mg levels were significantly different between the two groups (p = 0.044). The impact of HCV on the liver function was significantly different on GGT (p = 0.008). We examed the lipids and liver function level between the tacrolimus and the patients receiving cyclosporine-based immunosuppression and the total cholesterol (p = 0.005) and GOT (p = 0.05) were significantly different between the two groups. Hyperlipidemia was associated with 26% of patients taking tacrolimus-based immunosuppression, and 89% of those receiving cyclosporine; the difference was significant (p = 0.002). Regarding the effect of hyperlipidemia on liver enzymes, ALP (p = 0.006) and GGT (p = 0.0001) were significantly higher. Conclusion: Increases in hepatic enzymes, ALT and GGT indicate the damage to hepatocytes. Beside the increase of liver function, which is the main risk factor in hepatitis on HCV soil, the applied immunosuppressive therapy and hyperlipidemia lead to degradation of allograft function and long-term graft loss.

KW - Cyclosporine

KW - Hyperlipidemia

KW - Liver function

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=85060609110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060609110&partnerID=8YFLogxK

U2 - 10.1556/650.2019.31257

DO - 10.1556/650.2019.31257

M3 - Article

VL - 160

SP - 186

EP - 190

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 5

ER -